Morgan Stanley
IMMX icon

Morgan Stanley’s Immix Biopharma IMMX Stock Holding History

Morgan Stanley’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
159,474
+19,588
+14% +$182K ﹤0.01% 4956
2026
Q1 		$1.27M Buy
139,886
+13,264
+10% +$97.4K ﹤0.01% 5024
2025
Q4 		$662K Buy
126,622
+5,952
+5% +$24.5K ﹤0.01% 5374
2025
Q3 		$252K Sell
120,670
-4,249
-3% -$10.2K ﹤0.01% 5801
2025
Q2 		$259K Buy
124,919
+42,627
+52% +$85.8K ﹤0.01% 5748
2025
Q1 		$138K Sell
82,292
-8,759
-10% -$16.5K ﹤0.01% 5875
2024
Q4 		$200K Buy
91,051
+6,738
+8% +$12.3K ﹤0.01% 5785
2024
Q3 		$126K Buy
84,313
+25,856
+44% +$52K ﹤0.01% 5909
2024
Q2 		$116K Buy
58,457
+4,412
+8% +$10.1K ﹤0.01% 5912
2024
Q1 		$166K Buy
54,045
+37,877
+234% +$147K ﹤0.01% 5789
2023
Q4 		$112K Buy
16,168
+15,768
+3,942% +$71.4K ﹤0.01% 5896
2023
Q3 		$1.37K Buy
+400
New +$938 ﹤0.01% 7191
2023
Q1 		– Sell
-1
Closed -$2 – 7770
2022
Q4 		$2 Sell
1
-2
-67% -$3 ﹤0.01% 7856
2022
Q3 		$0 Buy
+3
New +$7 ﹤0.01% 7790

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's IMMX Position: Q2 2026 in Review

Morgan Stanley increased its Immix Biopharma (IMMX) stake by 14% in Q2 2026, buying an estimated $182K and bringing the position to 159,474 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #4956.

Morgan Stanley first reported a position in IMMX in Q3 2022 and has held it in 14 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Morgan Stanley held 159,474 shares of Immix Biopharma worth $1.64M as of Q2 2026.
  • Morgan Stanley bought 19,588 Immix Biopharma shares in Q2 2026, an estimated $182K.
  • Immix Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4956 holding.
  • Morgan Stanley first reported a position in Immix Biopharma in Q3 2022 and has held it in 14 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.